Skip to main content
SpringerLink
Log in

Cost-effective treatments for multiple sclerosis

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Celestin C, et al. Cost-effectiveness of alemtuzumab vs subcutaneous interferon beta-1a for treatment of active relapsing-remitting multiple sclerosis: payer perspective. 30th Congress of the European Committee for Treatment and Research in Multiple Sclerosis : abstr. P013, 14 Sep 2014. Available from: URL: http://www.professionalabstracts.com/msboston2014/planner/index.php?go=abstract&action=abstract_show&absno=1788&

  2. Palace J, et al. The long-term effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate: 6-year analysis of the UK MS risk-sharing scheme. 30th Congress of the European Committee for Treatment and Research in Multiple Sclerosis : abstr. LB1.2, 14 Sep 2014. Available from: URL: http://www.professionalabstracts.com/msboston2014/planner/index.php?go=abstract&action=abstract_show&absno=2201&

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost-effective treatments for multiple sclerosis. PharmacoEcon Outcomes News 714, 15 (2014). https://doi.org/10.1007/s40274-014-1636-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1636-y

Search

Navigation